Biomarker ID | 1156 |
PMID | 23826311 |
Year | 2013 |
Biomarker | Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773] |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate |
Type of Biomarker | Diagnostic |
Cohort | 125 samples were divided into a discovery set with 22 PCa, 14 Chronic Prostatis; 9 BPH and 5 Healthy Control samples and the remaining 48 PCa, 12 BPH, 11 CP, and 4HC samples into an independent test set |
Senstivity | NA |
Specificity | NA |
AUC | Training: 1.00 (95% CI .93–1.00) |
Accuracy | NA |
Level Of Significance | p< 0.0137 |
Method Used | capillary electrophoresis mass spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |